MicroRNA panels as diagnostic biomarkers for colorectal cancer: A systematic review and meta-analysis. 2022

Daniel Sur, and Shailesh Advani, and Dejana Braithwaite
Department of Medical Oncology, The Oncology Institute "Prof. Dr. Ion Chiricuţă" Cluj-Napoca, Cluj-Napoca, Romania.

Circulating microRNAs (miRNA) have emerged as promising diagnostic biomarkers for several diseases, including cancer. However, the diagnostic accuracy of miRNA panels in colorectal cancer (CRC) remains inconsistent and there is still lack of meta-analyses to determine whether miRNA panels can serve as robust biomarkers for CRC diagnosis. This study performed a systematic review and meta-analysis to evaluate the clinical utility of miRNA panels as potential biomarkers for the diagnosis of CRC. The investigation systematically searched PubMed, Medline, Web of Science, Cochrane Library, and Google Scholar (21-year span, between 2000 and 2021) to retrieve articles reporting the diagnostic role of miRNA panels in detecting CRC. Diagnostic meta-analysis of miRNA panels used diverse evaluation indicators, including sensitivity, specificity, Positive Likelihood Ratio (PLR), Negative Likelihood Ratio (NLR), Diagnostic Odds Ratio (DOR), and the area under the curve (AUC) values. Among the 313 articles identified, 20 studies met the inclusion criteria. The pooled estimates of miRNA panels for the diagnosis of CRC were 0.85 (95% CI: 0.84-0.86), 0.79 (95% CI: 0.78-0.80), 4.06 (95% CI: 3.89-4.23), 0.20 (95% CI: 0.19-0.20), 22.50 (95% CI: 20.81-24.32) for sensitivity, specificity, PLR, NLR, and DOR, respectively. Moreover, the summary receiver operating characteristics (SROC) curve revealed an AUC value of 0.915 (95% CI: 0.914-0.916), suggesting an outstanding diagnostic accuracy for overall miRNA panels. Subgroup and meta-regression analyses demonstrated that miRNA panels have the highest diagnostic accuracy within serum samples, rather than in other sample-types - with a sensitivity, specificity, PLR, NLR, DOR, and AUC of 0.87, 0.86, 7.33, 0.13, 55.29, and 0.943, respectively. Sensitivity analysis revealed that DOR values did not differ markedly, which indicates that the meta-analysis had strong reliability. Furthermore, this study demonstrated no proof of publication bias for DOR values analyzed using Egger's regression test (P > 0.05) and funnel plot. Interestingly, miR-15b, miR-21 and miR-31 presented the best diagnostic accuracy values for CRC with sensitivity, specificity, PLR, NLR, DOR, and AUC values of 0.95, 0.94, 17.19, 0.05, 324.81, and 0.948, respectively. This study's findings indicated that miRNA panels, particularly serum-derived miRNA panels, can serve as powerful and promising biomarkers for early CRC screening. [www.crd.york.ac.uk/prospero], identifier [CRD42021268172].

UI MeSH Term Description Entries

Related Publications

Daniel Sur, and Shailesh Advani, and Dejana Braithwaite
November 2022, Breast cancer research and treatment,
Daniel Sur, and Shailesh Advani, and Dejana Braithwaite
January 2019, Cancer management and research,
Daniel Sur, and Shailesh Advani, and Dejana Braithwaite
December 2019, The International journal of biological markers,
Daniel Sur, and Shailesh Advani, and Dejana Braithwaite
January 2019, Cancer management and research,
Daniel Sur, and Shailesh Advani, and Dejana Braithwaite
January 2014, PloS one,
Daniel Sur, and Shailesh Advani, and Dejana Braithwaite
January 2022, Frontiers in immunology,
Daniel Sur, and Shailesh Advani, and Dejana Braithwaite
June 2016, Scandinavian journal of immunology,
Daniel Sur, and Shailesh Advani, and Dejana Braithwaite
January 2015, International journal of clinical and experimental medicine,
Daniel Sur, and Shailesh Advani, and Dejana Braithwaite
March 2023, International journal of molecular sciences,
Daniel Sur, and Shailesh Advani, and Dejana Braithwaite
May 2023, BMC cancer,
Copied contents to your clipboard!